References

1) Lindqvist U et al. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet 2002; 41: 603 13.

2) Larsen NE et al. Clearance kinetics of a single injection cross-linked hylan-based viscosupplement in a rabbit model. Osteoarth Cart 2007; 15(Suppl. C): C64.

3) Brown TJ et al. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol 1991; 76: 125-134.

4) Edsman K et al. Intra-articular duration of DUROLANE^TM after single injection into the rabbit knee. Cartilage 2011;2(4):384-388.

DUROLANE is a registered trademark of Q-MED AB.
NASHA is a trademark of Q-MED AB.
The Bioventus logo is a registered trademark of Bioventus LLC. © 2012 Bioventus LLC

Indications

For the symptomatic treatment of mild to moderate osteoarthritis.

DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, toes, and the temporomandibular and facet joints.

DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, toes, and the temporomandibular and facet joints.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to 6 months but results may vary depending on various patient factors.